Sun Sells US Plant As It Tackles Post-Ranbaxy Consolidation
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharma has clinched a deal to sell a US plant as part of a consolidation drive in the wake of its purchase of rival Ranbaxy, amid improving investor sentiment toward the country's biggest drug company.